Drug Profile
Monoclonal antibody ABX-RB2
Alternative Names: ABX-RB2Latest Information Update: 24 Apr 2003
Price :
$50
*
At a glance
- Originator Abgenix
- Class Monoclonal antibodies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Transplant rejection
Most Recent Events
- 16 Aug 2000 Abgenix and SangStat sign an antibody therapy agreement
- 14 Apr 1999 Preclinical development for Autoimmune disorders in USA (Unknown route)
- 14 Apr 1999 Preclinical development for Transplant rejection in USA (Unknown route)